Biotech

Slope’s Hope Meely on the importance of a fully enabled clinical supply platform

Sponsors and CROs have historically been responsible for ensuring full chain of custody for their own clinical supply even though the clinical supply is typically outside of their control.  It is the burden of the Sponsors and CROs to determine the most efficient way to do that.

In this podcast, we have a conversation with Hope Meely, Chief Clinical Officer for Slope, to get a deeper insight into the technology of Slope’s platform and how it enhances patient-centric care within the clinical trial industry. Ms. Meely has over 20 years of experience in clinical research with a focus on clinical trial operations and a specialty in making clinical trial operations easier for research sites and sponsors through multiple-phase clinical trial projects. She joined the executive team of Slope to leverage the platform while supporting clinical trial innovation.

The features of Slope as a SaaS-based e-clinical supply chain management platform are highlighted. The discussion emphasizes that the product has produced a solution to the significant need of having an all-in-one platform that doesn’t lose visibility of the chain of custody at any point. Our expert discusses the difficulty of finding a vendor capable of handling the level of transparency needed for clinical trial projects while streamlining internal and external communications, given that only one vendor included the necessary features while prioritizing efficiency across the board.

Clinical studies are reaching a new level of complexity and budgetary difficulty. To combat these issues, Slope’s platform was designed to provide users with guided workflows to help to provide some level of standardization, prevent errors, and drive digital changes in the clinical trial space. Meely mentions that the main issue in the marketplace today is having a traceable chain of custody and compliance. Slope solves this problem by presenting multiple solutions, from generating reconciliation reports, predicting supply needs, and focusing on regulatory requirements while expanding communication simplification across departments and entire organizations when needed.

The editorial staff had no role in this post's creation.